Deutsche Bank AG Sells 80,130 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Deutsche Bank AG cut its holdings in IQVIA Holdings Inc. (NYSE:IQV) by 9.8% in the 1st quarter, Holdings Channel reports. The institutional investor owned 739,779 shares of the medical research company’s stock after selling 80,130 shares during the period. Deutsche Bank AG’s holdings in IQVIA were worth $130,423,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently bought and sold shares of the company. American National Bank & Trust bought a new position in IQVIA in the 1st quarter worth approximately $26,000. Golden State Wealth Management LLC boosted its position in shares of IQVIA by 295.5% in the first quarter. Golden State Wealth Management LLC now owns 174 shares of the medical research company’s stock valued at $31,000 after acquiring an additional 130 shares during the period. AllSquare Wealth Management LLC bought a new position in shares of IQVIA in the first quarter valued at approximately $33,000. ST Germain D J Co. Inc. boosted its position in shares of IQVIA by 66.1% in the first quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 76 shares during the period. Finally, GKV Capital Management Co. Inc. bought a new position in shares of IQVIA in the fourth quarter valued at approximately $39,000. 89.62% of the stock is owned by institutional investors.

IQVIA Trading Up 0.6%

IQV stock opened at $179.98 on Friday. The company has a market capitalization of $30.60 billion, a PE ratio of 26.05, a price-to-earnings-growth ratio of 1.97 and a beta of 1.30. IQVIA Holdings Inc. has a one year low of $134.65 and a one year high of $252.88. The company’s 50 day moving average price is $166.23 and its two-hundred day moving average price is $169.20. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.84 and a current ratio of 0.84.

IQVIA (NYSE:IQV) last posted its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 EPS for the quarter, topping the consensus estimate of $2.77 by $0.04. IQVIA had a net margin of 7.88% and a return on equity of 30.05%. The firm had revenue of $4.02 billion for the quarter, compared to the consensus estimate of $3.96 billion. During the same period last year, the firm posted $2.64 earnings per share. The business’s revenue was up 5.3% compared to the same quarter last year. As a group, analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current fiscal year.

Insider Activity at IQVIA

In other news, insider Eric Sherbet sold 5,800 shares of the firm’s stock in a transaction that occurred on Wednesday, July 23rd. The shares were sold at an average price of $190.05, for a total value of $1,102,290.00. Following the transaction, the insider owned 27,178 shares in the company, valued at approximately $5,165,178.90. This trade represents a 17.59% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, insider Keriann Cherofsky sold 549 shares of the firm’s stock in a transaction that occurred on Wednesday, July 23rd. The stock was sold at an average price of $191.53, for a total transaction of $105,149.97. Following the completion of the transaction, the insider owned 2,910 shares in the company, valued at $557,352.30. This represents a 15.87% decrease in their position. The disclosure for this sale can be found here. 1.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on IQV. Hsbc Global Res lowered shares of IQVIA from a “strong-buy” rating to a “hold” rating in a research report on Friday, April 25th. Redburn Partners set a $188.00 price objective on shares of IQVIA in a research report on Friday, May 23rd. Truist Financial raised their price objective on shares of IQVIA from $209.00 to $235.00 and gave the company a “buy” rating in a research report on Wednesday, July 23rd. Cowen reaffirmed a “buy” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Finally, William Blair reaffirmed an “outperform” rating on shares of IQVIA in a research note on Wednesday, July 23rd. Seven analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $228.62.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.